Toboroz
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Még nem toboroz
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· 3. fázis· The Netherlands Cancer Institute· Forrás
Toboroz
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· 3. fázis· BeOne Medicines· Forrás
Toboroz
T3-4-Hypo trial
2024-513883-24-00· 3. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Toboroz
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
2024-519354-36-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Toboroz
StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial
2024-517343-31-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.
NCT02371304· 3. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· 4. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
Ulipristal versus surgery for symptomatic uterine fibroids
2024-512602-26-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Fut, nem toboroz
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
NCT04225312· 4. fázis· Amsterdam UMC Stichting· Forrás
Fut, nem toboroz
PreVent-ACaLL
NCT03868722· 2. fázis· Rigshospitalet· Forrás
Toboroz
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· 4. fázis· Amsterdam UMC· Forrás
Fut, nem toboroz
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· 3. fázis· Genmab· Forrás
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Fut, nem toboroz
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Fut, nem toboroz
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261· 3. fázis· Acerta Pharma BV· Forrás
Fut, nem toboroz
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
NCT03348150· 3. fázis· The Netherlands Cancer Institute· Forrás